Findings

What do systematic reviews say?

7 questions · 7 findings · 1 reviews

Sort:Best matchNewest Highest certainty Download CSV

No studies found 0 · 0%GRADE not reported 0 · 0%Very low 0 · 0%Low 7 · 100%Moderate 0 · 0%High 0 · 0%

Summary of findings: insulin degludec vs insulin detemir

All‐cause mortality

1 finding from 1 review

(Ultra‐)long‐acting insulin analogues for people with type 1 diabetes mellitus 2021 · Cochrane Headline outcomes only
no estimate extracted
2 studies · 802 participants
Low

Summary of findings: insulin degludec vs insulin detemir

Health related quality of life the Uniscale and the Symptom Distress Scale (SDS); Better indicated by lower values

1 finding from 1 review

(Ultra‐)long‐acting insulin analogues for people with type 1 diabetes mellitus 2021 · Cochrane Headline outcomes only
no estimate extracted
1 study · 454 participants
Low

Summary of findings: insulin degludec vs insulin detemir

Severe hypoglycaemia

Summary of findings: insulin degludec showed no clear difference in severe hypoglycaemia (n/N) Definition: hypoglycaemia requiring third… compared with insulin detemir (low certainty).

1 finding from 1 review

(Ultra‐)long‐acting insulin analogues for people with type 1 diabetes mellitus 2021 · Cochrane Headline outcomes only
RR 1.17 [0.81, 1.69]
2 studies · 802 participants
Low

Summary of findings: insulin degludec vs insulin detemir

Non‐fatal myocardial infarction/stroke

1 finding from 1 review

(Ultra‐)long‐acting insulin analogues for people with type 1 diabetes mellitus 2021 · Cochrane Headline outcomes only
no estimate extracted
1 study · 453 participants
Low

Summary of findings: insulin degludec vs insulin detemir

Severe nocturnal hypoglycaemia (n/N) Definition: severe hypoglycaemia occurring 00:01‐05:59 (Davies 2014) or 23:00‐07:00 (BEGIN Young)

Summary of findings: insulin degludec showed no clear difference in severe nocturnal hypoglycaemia (n/N) Definition: severe… compared with insulin detemir (low certainty).

1 finding from 1 review

(Ultra‐)long‐acting insulin analogues for people with type 1 diabetes mellitus 2021 · Cochrane Headline outcomes only
RR 1.12 [0.51, 2.46]
2 studies · 802 participants
Low

Summary of findings: insulin degludec vs insulin detemir

Serious adverse events (n/N)

Summary of findings: insulin degludec showed no clear difference in serious adverse events (n/N) compared with insulin detemir (low certainty).

1 finding from 1 review

(Ultra‐)long‐acting insulin analogues for people with type 1 diabetes mellitus 2021 · Cochrane Headline outcomes only
RR 1.25 [0.76, 2.05]
2 studies · 802 participants
Low

Summary of findings: insulin degludec vs insulin detemir

HbA1c (%)

1 finding from 1 review

(Ultra‐)long‐acting insulin analogues for people with type 1 diabetes mellitus 2021 · Cochrane Headline outcomes only
no estimate extracted
2 studies · 802 participants
Low